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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive and
usually lethal lung disease characterized by fibroblast prolif-
eration and extracellular matrix accumulation (1). Its patho-
genesis remains poorly understood but is associated with a
predominance of Th2 cytokine and a paucity of Th1 cytokine
(2-4). Studies on immunopathology (2) and m-RNA expres-
sion (3, 4) have revealed that the lung tissues of IPF patients
show abnormally high levels of interleukin (IL)-4 and IL-5,
and a low level of interferon-γ(IFN-γ ). Flow cytometry anal-
ysis of intracellular cytokines showed a similar pattern in the
bronchoalveolar lavage (BAL) cells of IPF patients (5). The
role of Th2 cytokines, especially IL-4 and IL-13, in pulmonary
fibrosis has been clearly demonstrated by both in vivo and in
vitro experiments (6, 7). These two cytokines function via com-
plex receptor systems that include IL-4 receptor alpha (IL-
4Rα ), and IL-13 receptor alpha1 (IL-13Rα 1) (8). IL-13Rα 1
binds IL-13 in a complex with IL-4Rα 1 (9, 10). IL-13 recep-
tor α 2 (IL-13Rα 2) has a short cytoplasmic tail without intra-
cellular signaling motifs; thus, it may function as a decoy
receptor that inhibits the effects of IL-13 (10, 11). The down-
regulatory effect of IL-13Rα 2 has been demonstrated in ani-
mal models with IL-13-mediated tissue fibrosis (12) but has
not been shown in humans.
IPF and nonspecific interstitial pneumonia (NSIP) are the
two common types of idiopathic interstitial pneumonia (IIP).
However, compared with IPF, NSIP leads to less fibrosis (13,
14) and shows a better response to anti-inflammatory agents
such as steroids and anti-proliferative drugs (15, 16). There-
fore, the two diseases may induce different patterns of fibro-
sis-related cytokines. It has already been demonstrated that
NSIP and IPF lead to different levels of inflammatory cyto-
kines and CXC chemokines, such as IL-6, IL-8, epithelial
neutrophil-activating peptide 78, interferon gamma-inducible
protein 10, RANTES, and monocyte chemotactic protein-1
(17-20), but little is known about how Th2 and Th1 cytokines
and their receptors differ between the two conditions.
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Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia:
Clinical Implications for Lung Function
Idiopathic interstitial pneumonia (IIP) is characterized by varying degrees of inter-
stitial fibrosis. IL-13 and IL-4 are strong inducers of tissue fibrosis, whereas IFN-γ
has antifibrotic potential. However, the roles of these substances in IIP remain un-
known. IL-13, IL-4, and IFN-γwere measured in the BAL fluid of 16 idiopathic pul-
monary fibrosis (IPF) patients, 10 nonspecific interstitial pneumonia (NSIP) patients,
and 8 normal controls. The expression of IL-13 and IL-13Rα 1/α 2 in lung tissues was
analyzed using ELISA and immunohistochemistry. IL-13 levels were significantly
higher in IPF patients than the others (P<0.05). IL-4 levels were higher in both IPF
and NSIP patients than in normal controls (P<0.05), and IFN-γlevels were lower
in NSIP patients than in normal controls (P=0.047). IL-13 levels correlated inversely
with FVC% (r=-0.47, P=0.043) and DLCO% (r=-0.58, P=0.014) in IPF and NSIP
patients. IL-13 was strongly expressed in the smooth muscle, bronchial epithelium,
alveolar macrophages and endothelium of IPF patients. IL-13Rα 1, rather than IL-
13Rα 2, was strongly expressed in the smooth muscle, bronchial epithelium, and
endothelium of IPF patients. IL-13 and its receptors may contribute to the pathogen-
esis of fibrosis in IIP and appear to be related to the severity of the disease.
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We hypothesized that IFN-γ , IL-4, and IL-13 may be reg-
ulated differently and that IL-13Rα 1 and IL-13Rα 2 may be
expressed differently in IPF and NISP patients.
To test this hypothesis, we measured IL-4, IL-13, and IFN-
γlevels in the BAL fluid of IPF and NSIP patients and nor-
mal controls, and compared IL-13Rα 1 and IL-13Rα 2 expres-
sion in diseased lung tissues using immunohistochemical
staining.
MATERIALS AND METHODS
Study populations
The study population consisted of 16 patients with IPF,
ten with idiopathic NSIP, and eight normal controls. All sub-
jects were given a chest radiograph, HRCT, pulmonary func-
tion test, and blood gas analysis (Table 1). The diagnoses of
IPF and NSIP were based on the international consensus state-
ment (21). Two of the NSIP patients had inflammation and
fibrotic type pneumonia (group II) and eight had interstitial
fibrotic type pneumonia (group III). BAL and open -lung or
video-guided thoracoscopic biopsies were performed on all
IIP patients. BAL was performed at least 3 days before lung
biopsy and without any immunosuppressive therapies. In
normal subjects, BAL was performed on the right middle
lobe. Exclusion criteria consisted of other known causes of
interstitial lung disease, such as drug reactions, environmen-
tal exposures, and collagen vascular diseases. The normal con-
trols were all healthy volunteers, free of symptoms, not tak-
ing any medications, and who had normal chest radiographs.
For immunohistochemical staining, the healthy tissues of
biopsies of solitary pulmonary nodules were used.
Measurements of IL-13, IL-4, and IFN-γ γconcentrations
in Bronchoalveolar lavage (BAL) fluids
BAL was performed as previously described (17), using a
flexible fiberoptic bronchoscope (Olympus B2-10; Olympus
Optical Co., Tokyo, Japan). Briefly, all study subjects were
pretreated with atropine (0.5 mg) immediately before the
BAL procedure. Bronchial trees were instilled four times with
50 mL of normal saline, and fluid was removed each time
by gentle suction with negative pressure below 50 mmHg.
The total volume of recovered fluids was measured, and the
supernatant was separated from the cell pellets by centrifu-
gation at 500×g for 5 min. The supernatants were frozen
and stored at -80℃for later use. A differential count of 500
cells was performed on slides prepared by cytocentrifugation
and Diff-Quik staining (Scientific Products, Gibbstowne,
NJ, U.S.A.). No complications were experienced during the
BAL procedures. 
The IL-13, IL-4, and IFN-γlevels were measured using
quantitative sandwich enzyme immunoassays with ELISA
kits (BD Bioscience, San Diego, CA, U.S.A.), according to the
manufacturer’s recommendations. The detection limits were
2.0 pg/mL, 3.5 pg/mL, and 1.0 pg/mL for IL-4, IL-13, and
IFN-γ , respectively, and values below these thresholds were
assigned a value of 0 pg/mL. For validation of assay, we per-
formed spiking experiment using 10 samples and the recov-
ery rates of IL-4, IL-13, and IFN-γwere 86.2±0.1%, 93.5±
0.6%, 89.3±0.8%, respectively. The inter-assay coefficient
of variability for all assays was less than 10%, and the intra-
assay coefficient of variability was less than 10% across the
range of concentrations.
Immunohistochemical staining 
A VectaStatin goat ABC Elite kit (Vector Laboratories,
Burlingame, CA, U.S.A.) was used for immunostaining. Tis-
sue sections (5 μ m) were deparaffinized, endogenous peroxi-
dase was blocked with 1.4% H2O2in MeOH for 30 min, and
nonspecific binding was blocked with 1.5% normal rabbit
serum for 30 min. The sections were incubated with goat poly-
clonal antihuman IL-13 antibody (1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA, U.S.A.) and goat polyclonal anti-
human IL-13Rα 1 and IL-13Rα 2 antibody (1:200, R&D, Min-
neapolis, MN, U.S.A.) at 4℃ for 16 hr. After washing with
TBS, the sections were sequentially incubated with biotiny-
lated rabbit anti-goat immunoglobulin G (H+L) (1:200, Vec-
tor Laboratories, Burlingame, CA, U.S.A.) and avidin-biotin
peroxidase complex (1:50, ABC kit, Vector Laboratories) for
30 min. The color reaction was developed with 3,3′ -diamino-
Data are presents as mean±SEM.
*P<0.05 compared with normal control; 
� P<0.01 compared with normal
control.
IPF, idiopathic pulmonary fibrosis; CS, current smoker; ES, ex-smoker;
NS, never-smoker; TLC, total lung capaciy; FVC, forced vital capacity;
DLCO, diffusing capacity of carbon monoxide; NSIP, nonspecific inter-
stitial pneumonia.
Normal control  NSIP IPF
Sex (M/F) 5/3   3/7 7/9
Age (yr) 48.1±7.11 49.4±7.55 52.6±4.51
Symptom duration (months) 2.6±0.54 7.3±2.2
Smoking (CS:ES:NS) 2:2:4 1:1:8 2:4:10
TLC (% pred.) 98.6±3.26 69.4±4.01* 69.9±7.12*
FVC (% pred.) 102.4±2.62 60.4±9.19* 60.7±4.38*
DLCO (% pred.) 99.0±3.14 61.9±7.17* 52.2±12.19*
D(A-a)O2 mmHg 27.2±10.6 36.7±12.4
BAL cell profile
Total cell count×10
5/mL 2.19±0.8 4.62±1.5* 4.81±1.1*
Macrophage (%) 93.5±6.5 83.9±9.7 75.4±10.1
Neutrophil (%)   2.97±1.7 8.05±4.6* 12.8±5.6*
Lymphocyte (%) 2.86±0.9 5.94±1.9 5.24±1.2
Eosinophil (%)  0.55±0.2 2.46±1.8 4.99±0.9
�
Table 1. Demographic characteristics, lung function and bron-
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benzidine tetrachloride (Zymed Laboratories, South San Fran-
cisco, CA, U.S.A.), and Harris hematoxylin stain was applied
as a counter stain. The intensity of immunostaining was grad-
ed from absent (-) to strongly positive (+++) for the follow-
ing tissues: alveolar epithelium, bronchial epithelium, smooth
muscle, alveolar macrophage, endothelial cells, and intersti-
tium. Grading was as follows: (-), no staining; (±), very fain-
tly brown; (+), faintly brown; (++), moderately brown; and
(+++), dark brown. Histological sections were assessed inde-
pendently by two observers who were blind to the clinical
information of the study subjects. 
Statistics
The SPSS/PC+ program (Chicago, IL, U.S.A.) was used
for statistical analyses. Differences between groups were com-
pared with the nonparametric Kruskal-Wallis test for con-
tinuous data. Significant relationships between groups were
further analyzed using the Mann-Whitney U test. Spearman’s
rank correlation was used to analyze the relationships of IL-4,
IL-13, and IFN-γconcentrations to the lung functions. Dif-
ferences were considered significant at P<0.05. The data are
expressed as mean±SEM.
RESULTS
Clinical profiles of study subjects and cellular proportions
in BAL fluids
The clinical and BAL profiles are summarized in Table 1.
Age, smoking status, and sex ratio were comparable among
the three groups. The NSIP and IPF patients had a signifi-
cant reduction in forced vital capacity (FVC), total lung capac-
ity (TLC), and diffusing capacity of carbon monoxide (DLCO)
compared with controls (P<0.05). Both the cell number and
percentage of neutrophils in 1 mL of BAL fluid were signif-
icantly higher in patients with NSIP and in those with IPF
than in control subjects (P<0.01 and P<0.05, respectively).
There were no difference in the percentages of lymphocytes
and macrophages between NSIP and IPF patients, but IPF
patients had a significantly higher percentage of eosinophils
than controls (P<0.01).
IL-4, IL-13, and IFN-γ γconcentrations in BAL fluids
IL-13 activity was detected in the BAL fluid of all patients
and in seven of the eight control subjects. The IL-13 levels
were higher in IPF patients than in NSIP patients (249.0±
83.1 vs. 137.7±37.9 pg/mL, P=0.032) and controls (249.0
±83.1 vs. 49.0±13.1 pg/mL, P=0.012). The IL-13 levels
were also higher in NSIP patients than in controls (P=0.041;
Fig. 1A). IL-4 activity was detected in 12 of 16 IPF patients,
eight of ten NSIP patients, and three of eight controls. The
mean IL-4 level was significantly higher in the IPF and NSIP
groups than in the control group (16.3±4.5 and 12.3±3.35
pg/mL vs. 4.67±2.28 pg/mL, P=0.008 and P=0.034, res-
pectively). The IL-4 level was not significantly different bet-
ween the IPF and NSIP groups (P>0.05; Fig. 1B). IFN-γ ac-
tivity was detected in 14 of 16 IPF patients, nine of ten NSIP
patients, and seven of eight controls. Both patient groups had
low INF-γlevels compared with the control group (7.72±
3.02 and 3.82±1.59 pg/mL vs. 11.32±3.64 pg/mL; Fig.
1C), but only the difference between NSIP patients and con-
trols was significant (P=0.047). The IL-13 level was inverse-
ly correlated with DLCO (% pred) (n=26, r=-0.58, P=0.014)
and FVC (% pred) (n=26, r=-0.47, P=0.043) in NSIP and
IPF patients (Fig. 2). Neither the IL-4 nor INF-γlevel cor-
related with the physiological parameters (data not shown).
Expression of IL-13 and IL-13Rα α 1/α α 2 detected by
immunohistochemical staining
Immunohistochemical staining of IL-13, IL-13Rα 1, and
Fig. 1. IL-4, IL-13, and IFN-γ levels in the BAL fluids of IPF and NSIP patients and of normal controls. Horizontal bars represent the mean
levels of the three groups.
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IL-13Rα 2 was performed in the lung tissues of controls (n=
4), IPF patients (n=6), and NSIP patients showing fibrosis
(n=6). To avoid the smoking effect, never smokers were select-
ed from the study subjects. Control subjects had undergone
a lobectomy to remove localized solitary pulmonary nodules
(two lung cancer and two tuberculoma). Both IL-13 and IL-
13Rα 1 were strongly expressed in the bronchial epithelial
cells, alveolar macrophages, endothelial cells, and smooth mus-
cle of all patients (Fig. 3), although semiquantitative evalu-
ation showed that their intensities were much stronger in IPF
patients than in NSIP patients (Table 2). IL-13Rα 2 showed
the same pattern of expression as IL-13Rα 1 but weaker stain-
ing in both patient groups (Table 2, Fig. 3). Neither IL-13Rα 1
nor IL-13Rα 2 expression was detected in the four control lung
tissues.
DISCUSSION
We demonstrated that IL-4 and IL-13 levels were higher
Fig. 3. Immunohistochemical analysis of IL-13 and IL-13Rα 1/IL-13Rα 2 expression in lung tissues from patients with IPF and from controls.
IL-13 was only negligibly expressed in controls (A) but was strongly expressed in the smooth muscle (B), bronchial epithelium, especially
the hyperplastic regenerating epithelium (C), alveolar macrophages (D), endothelium (E), and interstitum (F) of IPF patients. IL-13Rα 1 was
strongly expressed by the bronchial epithelium and smooth muscle of IPF patients (G). IL-13Rα 2 was weakly expressed in the same regions
of IPF patients (H). Magnification: ×20 (A), ×40 (B), ×100 (C, F-H), and ×200 (D, E).
A B C D
E F G H
500 μ m 100 μ m 50 μ m 50 μ m
Fig. 2. Correlation between IL-13 levels and FVC (% pred) and DLCO (% pred) in patients with IPF and NSIP. Open and closed circles
represent NSIP and IPF patients, respectively. IL-13 showed a significant inverse correlation with FVC (% pred) (r=-0.47, P=0.043) and
DLCO (% pred) (r=-0.58, P=0.014).
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in the BAL fluids of NSIP and IPF patients than in that of
healthy subjects and that INF-γlevels were lowest in the NSIP
groups. These findings suggest that there is a predominance
of Th2 over Th1 cytokines in the lungs of NSIP patients, as
demonstrated in IPF patients of previous studies (2-4). In the
present study, the mean IL-13 level was higher in patients
than in controls, consistent with the reports of Jakubzick et
al. (4), who demonstrated that IL-13 gene expression was high-
er in lung biopsies of IPF and NSIP patients. However, in
our study, the mean IL-13 level was higher in IPF patients
than in NSIP patients, whereas Jakubzick et al. (24) reported
no significant differences in IL-13 gene expression between
the two patient groups. In both studies, IL-4 levels were
comparable between the two groups.
In addition, the IL-13 (and not IL-4) level was inversely
correlated with physiological derangement, including decreas-
es in DLCO and lung volume. This novel finding (Fig. 2) sug-
gests that IL-13, rather than IL-4, may be associated with
functional derangement in the patients with IPF and NSIP.
Several studies on animal models have suggested a compre-
hensive role for IL-13, rather than IL-4, in pulmonary fibro-
sis. Neutralization of IL-13, but not IL-4 alone, attenuated
pulmonary fibrosis in a bleomycin-induced pulmonary fibro-
sis model (22). In response to fluorescein isothiocyanate expo-
sure, IL-4 (-/-) mice developed fibrosis, whereas IL-13 (-/-)
mice were significantly resistant to fibrosis (23). These results,
and the fact that IPF is associated with more fibrotic lung
lesion than is NSIP, suggest that IL-13, rather than IL-4, may
be responsible for the degree of fibrosis in IIP patients, as seen
in our study. Indeed, administrating a chimeric protein, com-
prising human IL-13 and a truncated version of an exotoxin
from Pseudomonas (IL13-PE), as a therapeutic agent significant-
ly attenuated fibrosis (24). IL-13 may induce pulmonary fibro-
sis directly (25) or indirectly through TGF (beta)-1 (26) and
several types of MMP (27). 
Receptor binding chains for IL-13 include IL-13 Rα 1 and
IL-13Rα 2 (11). IL-13 Rα 1 binds IL-13 with low affinity,
whereas the co-expression of IL-13Rα 1 and IL-4Rαresults in
the formation of a high-affinity receptor signaling complex
that renders a variety of cells (e.g., mast, eosinophil, endothe-
lial, fibroblast, smooth muscle, and epithelial cells) respon-
sive to IL-13 (28). In the present study, both IL-13Rα 1 and
IL-13Rα 2 were expressed in the bronchial epithelial cells,
alveolar macrophages, endothelial cells, and smooth muscles
and interstitium of all IPF and NSIP patients, consistent with
Jakubzick et al. (4), who found that both proteins were strong-
ly expressed in the interstitium of the lung and that IL-13R
α 2 was also strongly expressed in the lung epithelium and
in mononuclear cells.
The effects of IL-13 are mediated by a complex receptor
system, which includes IL-4Rαand IL-13Rα 1, via STAT6
activation (10, 11). IL-13Rα 2 has a short cytoplasmic tail
without intracellular signaling motifs that bind to STAT6
(10, 11) thus, this receptor was expected to compete with the
IL-4Rα -/IL-13Rα 1 complex and dampen the IL-13-medi-
ated response (29). At present, however, it is not clear why
the greatly increased expression of IL-13Rα 2, particularly in
IPF patients, fails to curtail the profibrotic actions of IL-13.
It is possible that the natural antagonism of IL-13Rα 2 is lost
in patients with IIP as a result of post-translational modifica-
tions of this decoy receptor. Or perhaps, as a result of these
modifications, the IL-13Rα 2 subunit takes on an abnormal
signaling role in IPF. Fichtner-Feigl et al. (30) recently de-
monstrated that IL-13 is involved in the activation of the
TGFβ 1 promoter via IL-13Rα 2. Furthermore, blocking IL-
13 Rα 2 signaling with siRNA led to a down regulation of
TGFβ 1 production and collagen deposition in bleomycin-
induced lung fibrosis (30). This result indicates that IL-13R
α 2 can augment fibrosis via TGFβmodulation, which con-
tradicts other studies (12, 29).
The present study did not directly evaluate the role of IL-
13Rα 2 as a protector against or inducer of fibrosis in IIP. We
demonstrated the increased expression of IL-13Rα 1 and IL-
13Rα 2 in the two types of IIP, and no expression in controls,
indicating that both types of receptors are induced in the tis-
sues of people with IIP. However, the intensity of these two
receptors was significantly lower in NSIP patients than in
IPF patients. Furthermore, IL-13Rα 1 was strongly expressed
in the epithelium, smooth muscle, and alveolar macrophages
of both patient groups, whereas IL-13Rα 2 was only weakly
expressed (Fig. 2, Table 2), suggesting that differences in the
expression of IL-13Rα 1 and IL-13Rα 2 may help explain the
varying degrees of lung fibrosis between the two conditions.
A possible limitation of our study is that the differences in
IL-13 values for the BAL fluids of IIP patients and controls
(as determined by ELISA) may have been affected by the pres-
ence of soluble isoforms of the IL-13 receptor subunits. There
are many potential complications for measuring cytokine pro-
teins in whole lung homogenates; for example, the presence
of soluble decoy receptors and post-translational modifica-
Alveolar 
epithe- 
lium
Bron-
chiolar
epithe-
lium
Alveolar 
macro-
phage
Endo-
thelial 
cells
Smooth
muscle
Inter-
stitium 
IL-13
IPF (n=6) ++ +++ +++ +++ +++ ++
NSIP (n=6) + + + + + +
Controls (n=4) - ±±-- ±
IL-13Rα 1/Rα 2
IPF (n=6) +/- +++/+ +++/++ +++/+ +++/+ ++/+
NSIP (n=6) +/± +/+ ++/± ++/± +/± +/±
Controls (n=4) -/- ±±-/- -/- -/-
Table 2. Immunostaining for IL-13, IL-13Rα 1, and IL-13Rα 2 from
IPF, NSIP and normal controls  lung specimens 
Data are presented as - (absent) to +++ (intense) staining.
IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneu-
monia. tions of the cytokine proteins can render the proteins unde-
tectable by ELISA. Small numbers of NSIP and IPF in this
study also regarded another limitation. 
In conclusion, IL-13 levels were significantly elevated and
inversely correlated with DLCO and FVC in both IPF and
NSIP patients. Moreover, IL-13Rα 1 and IL-13Rα 2 were
strongly expressed in the lung tissues of IPF and NSIP pati-
ents. However, IL-13 and the two receptors were more strong-
ly expressed in patients with IPF than in those with NSIP.
These results suggest that the elevation of IL-13 elevation and
the concomitant expression of IL-13Rα 1 and IL-13Rα 2 may
be associated with the pathogenesis of both IPF and NSIP.
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